BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 38430889)

  • 1. Targeted modulation of gut and intra-tumor microbiota to improve the quality of immune checkpoint inhibitor responses.
    Wang W; Fan J; Zhang C; Huang Y; Chen Y; Fu S; Wu J
    Microbiol Res; 2024 May; 282():127668. PubMed ID: 38430889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.
    Wu J; Wang S; Zheng B; Qiu X; Wang H; Chen L
    Front Immunol; 2021; 12():669150. PubMed ID: 34267748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the gut microbiota in tumor, immunity, and immunotherapy.
    Xie Y; Liu F
    Front Immunol; 2024; 15():1410928. PubMed ID: 38903520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.
    Borgers JSW; Burgers FH; Terveer EM; van Leerdam ME; Korse CM; Kessels R; Flohil CC; Blank CU; Schumacher TN; van Dijk M; Henderickx JGE; Keller JJ; Verspaget HW; Kuijper EJ; Haanen JBAG
    BMC Cancer; 2022 Dec; 22(1):1366. PubMed ID: 36585700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors.
    Najafi S; Majidpoor J; Mortezaee K
    Life Sci; 2022 Dec; 310():121138. PubMed ID: 36309224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Challenge of ICIs Resistance in Solid Tumours: Could Microbiota and Its Diversity Be Our Secret Weapon?
    Roberto M; Carconi C; Cerreti M; Schipilliti FM; Botticelli A; Mazzuca F; Marchetti P
    Front Immunol; 2021; 12():704942. PubMed ID: 34489956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiome affects the response to immunotherapy in non-small cell lung cancer.
    Ren S; Feng L; Liu H; Mao Y; Yu Z
    Thorac Cancer; 2024 May; 15(14):1149-1163. PubMed ID: 38572783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Manipulating the gut and tumor microbiota for immune checkpoint inhibitor therapy: from dream to reality.
    Guillot N; Roméo B; Manesh SS; Milano G; Brest P; Zitvogel L; Hofman P; Mograbi B
    Trends Mol Med; 2023 Nov; 29(11):897-911. PubMed ID: 37704493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complex interactions between the microbiome and cancer immune therapy.
    Schwartz DJ; Rebeck ON; Dantas G
    Crit Rev Clin Lab Sci; 2019 Dec; 56(8):567-585. PubMed ID: 31526274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut Microbiota in Cancer Immune Response and Immunotherapy.
    Zhou CB; Zhou YL; Fang JY
    Trends Cancer; 2021 Jul; 7(7):647-660. PubMed ID: 33674230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy.
    Yang Y; An Y; Dong Y; Chu Q; Wei J; Wang B; Cao H
    EBioMedicine; 2024 Feb; 100():104967. PubMed ID: 38241975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition.
    Guardamagna M; Berciano-Guerrero MA; Villaescusa-González B; Perez-Ruiz E; Oliver J; Lavado-Valenzuela R; Rueda-Dominguez A; Barragán I; Queipo-Ortuño MI
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Microbiome in Advanced Melanoma: Where Are We Now?
    Fortman DD; Hurd D; Davar D
    Curr Oncol Rep; 2023 Sep; 25(9):997-1016. PubMed ID: 37269504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut microbiota and immunotherapy of renal cell carcinoma.
    Bibbò S; Porcari S; Del Vecchio LE; Severino A; Mullish BH; Ianiro G; Gasbarrini A; Cammarota G
    Hum Vaccin Immunother; 2023 Dec; 19(3):2268982. PubMed ID: 37955340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The Gut Microbiota Metabolite A Enhances the Anti-Tumor Effects of Anti-PD-1 Antibody Therapy through Immune Modulation].
    Hosonuma M; Murayama M; Yoshimura K
    Gan To Kagaku Ryoho; 2023 Sep; 50(9):960-964. PubMed ID: 37800288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut microbiota: impacts on gastrointestinal cancer immunotherapy.
    Lau HCH; Sung JJ; Yu J
    Gut Microbes; 2021; 13(1):1-21. PubMed ID: 33435800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revealing the therapeutic properties of gut microbiota: transforming cancer immunotherapy from basic to clinical approaches.
    Hazra R; Chattopadhyay S; Mallick A; Gayen S; Roy S
    Med Oncol; 2024 Jun; 41(7):175. PubMed ID: 38874788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.
    Rezasoltani S; Yadegar A; Asadzadeh Aghdaei H; Reza Zali M
    Cancer Med; 2021 Feb; 10(3):1141-1154. PubMed ID: 33369247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies.
    Lu Y; Yuan X; Wang M; He Z; Li H; Wang J; Li Q
    J Hematol Oncol; 2022 Apr; 15(1):47. PubMed ID: 35488243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
    Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
    Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.